Short-term triple therapy with azithromycin for Helicobacter pylori eradication: Low cost, high compliance, but low efficacy

BMC Gastroenterology

Volumn 8, Issue , 2008, Pages

  Silva, Fernando M ^a   Eisig, Jaime N ^a   Teixeira, Ana Cristina S ^a   Barbuti, Ricardo C ^a   Navarro Rodriguez, Tomás ^a   Mattar, Rejane ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; OMEPRAZOLE; UREA; UREASE;

ADULT; AGED; ARTICLE; BRAZIL; CONTROLLED STUDY; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NAUSEA; PATIENT COMPLIANCE; PEPTIC ULCER; TREATMENT DURATION; TREATMENT OUTCOME; UPPER GASTROINTESTINAL TRACT; UREA BREATH TEST; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; DUODENUM ULCER; ECONOMICS; MICROBIOLOGY; MIDDLE AGED; STATISTICS;

ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; AZITHROMYCIN; BRAZIL; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; DRUG THERAPY, COMBINATION; DUODENAL ULCER; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PATIENT COMPLIANCE; PEPTIC ULCER; TREATMENT OUTCOME;

EID: 46349097937     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-8-20     Document Type: Article

References (62)

1. NIH Consensus Development Panel on H. pylori in peptic ulcer disease Helicobacter pylori in peptic ulcer disease JAMA 1994, 272:65-69 10.1001/ jama.272.1.65 8007082
2. Malfertheiner P Megraud F O'Morain C Hungin APS Jones R Axon A Grahan DY Tytgat GI European Helicobacter pylori Study Group (EHPSG) Current concepts in the management of Helicobacter pylori infection - The Maastricht 2 - 2000 Consensus report Aliment Pharmacol Ther 2002, 16:167-80 10.1046/j.1365-2036.2002.01169.x 11860399
3. Lam SK Talley NJ Report of the 1997 ASIA Pacific Consensus Conference on the management of Helicobacter pylori infection J Gastroenterol Hepatol 1998, 13:1-12 10.1111/j.1440-1746.1998.tb00537.x 9737564
4. Hunt RH Fallone CA Veldhuyzan van Zanten S Sherman P Smaill F Flook N Thomson A CHSG 2004 participants Canadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori - an evidence-based evaluation of six topics relevant to clinical out comes in patients evaluated for H. pylori infection Can J Gastroenterol 2004, 18:547-54 15457293
5. Coelho LVG Zaterka S representatives of the Brazilian Federation of Gastroenterology and Brazilian Nucleus for the study of Helicobacter pylori Second Brazilian Consensus Conference on Helicobacter pylori Infection Arq Gastroenterol 2005, 42:128-32 16127570
6. Coelho LGV Leon-Barua R Quigley EMM Latin-American Consensus Conference on Helicobacter pylori infection Am J Gastroenterol 2000, 95:2688-91 11051336
7. Unge P Berstad A Pooled analysis of anti-Helicobacter pylori treatment regimens Scand J Gastroentrol Suppl 1996, 220:27-40 8898433 10.3109/ 00365529609094747
8. Pipkin GA Williamson R Wood JR Review article: One-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori Aliment Pharmacol Ther 1998, 12:823-37 10.1046/j.1365-2036.1998.00405.x 9768524
9. Chiba N Rao BV Rademaker JW Hunt RH Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori Am J Gastroenterol 1992, 87:1716-27 1449132
10. Guo CY Wu YB Liu HL Wu JY Zhong MB Clinical evaluation of four one-week triple therapy regimens in eradicating Helicobacter pylori infection World J Gastroenterol 2004, 10:747-9 14991953
11. Cammarota G Cianci R Cannizzaro O Cuoco L Pirozzi G Gasbarrini A Armuzzi A Zocco MA Santarelli A Arancio F Gasbarrini G Efficacy of two one-week rabeprazole/levoflaxacin-based triple therapies for Helicobacter pylori infection Aliment Pharmacol Ther 2000, 14:1339-43 10.1046/ j.1365-2036.2000.00846.x 11012480
12. Glupczynski I Burette A Drug therapy for Helicobacter pylori infection: Problems and pitfalls Am J Gastroenterol 1990, 85:1545-51 2174642
13. Cutler AF Schubert TT Patient's factors affecting Helicobacter pylori eradication with triple therapy Am J Gastroenterol 1993, 88:505-9 8470629
14. Pipkin GA Williamson R Wood JR Review article: One-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori Aliment Pharmacol Ther 1998, 12:823-837 10.1046/j.1365-2036.1998.00405.x 9768524
15. Qasin A O'Morain CA Review article: Treatment of Helicobacter pylori infection and factors influencing eradication Aliment Pharmacol Ther 2002 (suppl 1):24-30 10.1046/j.1365-2036.2002.0160s1024.x
16. Vakil N Helicobacter pylori: Factors affecting eradication e recurrence Am J Gastroenterol 2005, 100:2393-4 10.1111/j.1572-0241.2005.00286.x 16279890
17. Queiroz DMM Coimbra RS Mendes EN Rocha GA Alves VM Oliveira CA Lima Júnior GF Metronidazole resistant Helicobacter pylori in a developing country Am J Gastroenterol 1993, 88:322-3 8424447
18. Mendonça S Ecclissato C Sartori MS Godoy AP Guerzone RA Degger M Pedrazzoli J Jr Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil Helicobacter 2000, 5:79-83 10.1046/ j.1523-5378.2000.00011.x 10849055
19. Risi Júnior JB Nogueira RP As condições de saúde no Brasil - Retrospecto 1979 a 1995 Rio de Janeiro: Editora Fiocruz 2000 http://www.fiocruz.br/editora/media/04-CSPB02.pdf
20. Quadros WJ Antunes DJN Classes sociais e distribuição de renda no Brasil dos anos noventa. Cadernos do CESIT 2001 n 30 http://www.eco.unicamp.br/Downloads/publicacoes/cesit/ cadernodoCESIT30.pdf
21. Salário Mínimo e distribuição de renda Nota técnica - DIEESE 2005 http://www.dieese.org.br/notatecnica/ notatecSMDR.pdf n.6
22. Huang J Hunt RH The importance of clarithromycin dose in the management of Helicobacter pylori infection: A meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxicillin or metronidazole Aliment Pharmacol Ther 1999, 13:719-29 10.1046/ j.1365-2036.1999.00530.x 10383500
23. Goddard AF Spiller RC Helicobacter pylori eradication in clinical practice: One-week low-dose triple therapy is preferable to classical bismuth based triple therapy Aliment Pharmacol Ther 1996, 10:1009-13 10.1046/j.1365-2036.1996.95267000.x 8971303
24. Peitz U Sulliga M Wolle K Leodolter A Von Armim U Kahl S Stolte M Börsch G Labens J Malfertheiner P High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: Impact of two second-line therapies in a randomized study Aliment Pharmacol Ther 2002, 16:315-24 10.1046/ j.1365-2036.2002.01173.x 11860415
25. Coelho LGV Mattos AA Francisconi CFM Castro LP Andre SB Efficacy of the dosing regimen of pantoprazole 40 mg, amoxicillin 1000 mg and clarithromycin 500 mg, twice daily for 7 days, in the eradication of the Helicobacter pylori in patients with peptic ulcer Arq Gastroenterol 2004, 41:71-6 15499429
26. Ecclissato T Marchioretto MAM Mendonça S Godoy AP Guersoni RA Deguer M Piovesan H Ferraz JG Pedrazzoli J Increased primary resistance to recommended antibiotics negatively affects Helicobacter pylori eradication Helicobacter 2002, 7:53-9 10.1046/j.1523-5378.2002.00056.x 11886474
27. Magalhaes PP Queiroz DMM Barbosa DVC Rocha GA Mendes EN Santos A Valle Corrêa PR Camargos Rocha AM Martins Teixeira L Affonso de Oliveira C Helicobacter pylori primary resistance to Metronidazole and Clarithromycin in Brazil Antimicrob Agents Chemother 2002, 46:2021-3 127243 12019131 10.1128/AAC.46.6.2021-2023.2002
28. Godoy APO Ribeiro ML Benvengo YHB Vitiello L Miranda MC Mendonça S Pedrazzoli J Jr Analysis of antimicrobial susceptibility and virulence factors in Helicobacter pylori clinical isolates BMC Gastroenterol 2003, 3:20 194586 12911839 10.1186/1471-230X-3-20
29. Retsema J Girard A Schelkly W Manousos M Anderson M Bright G Borovoy R Brennan L Mason R Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms Antimicrob Agents Chemother 1987, 31:1939-47 175832 2449865
30. Blandizzi C Malizia T Gherardi G Costa F Marchi S Marveggio C Natale G Senesi S Bellini M Maltinti G Campa M Tacca MD Gastric mucosal distribution and clinical efficacy of azithromycin in patients with Helicobacter pylori related gastritis J Antimicrob Chemother 1998, 42:75-82 10.1093/jac/42.1.75 9700531
31. Di Mario F Dal Bó N Grassi AS Cannizzaro O Armuzzi A Gasbarrini A Addolorato G Gasbarrini GB Azithromycin for the cure of Helicobacter pylori infection Am J Gastroenterol 1996, 91:264-7 8607490
32. Caselli M Trevisani L Tursi A Sartori S Ruina M Luzzi I Gaudenzi P Alvisi V Gasbarrini G Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori Eur J Gastroenterol Hepatol 1997, 9:45-8 9031898
33. Chey WD Fisher L Barnett J Delvalle J Elta GH Hasler WL Nostrant T Palaniappan J Scheiman J Low-versus high-dose azithromycin triple therapy for Helicobacter pylori infection Aliment Pharmacol Ther 1998, 12:1263-7 10.1046/j.1365-2036.1998.00422.x 9882036
34. Calabrese C Di Febo G Areni A Scilapi C Biasco G Miglioni M Pantoprazole, azithromycin and tinidazole: Short duration triple therapy for eradication of Helicobacter pylori infection Aliment Pharmacol Ther 2000, 14:1613-17 10.1046/j.1365-2036.2000.00879.x 11121909
35. Chahine C Moukhachen O Chedid M Araj GF Sharara AI Ultrashort regimen of lansoprazole-amoxicillin-azithromycin for eradicating Helicobacter pylori Am J Health Syst Pharm 2001, 58:1819-23 11596697
36. Sullivan B Coyle W Nemec R Dunteman T Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori Am J Gastroenterol 2002, 97:2536-9 10.1111/ j.1572-0241.2002.06036.x 12385435
37. Coelho LG Vieira WL Passos MC Chausson Y Castro FJ Franco JM Yazaki FR Costa AC Andrade JM Castro LP Azithromycin, furazolidone and omeprazole: a promising low-dose, low cost, short-term, anti-H. pylori triple therapy Gastroenterology 1998, 114:G0382 10.1016/S0016-5085(98)80379-X
38. Silva FM Eisig JN Chether EZ da Silva JJ Laudanna AA Low efficacy of an ultra-short term, once-daily dose triple therapy with omeprazole, azithromycin and secnidazole for Helicobacter pylori eradication in peptic ulcer Rev Hosp Clin Fac Med Sao Paulo 2002, 57:9-14 12170343
39. Ministério da Saúde. Farmácia Popular do Brasil http://portal.saude.gov.br/portal/arquivos/pdf/ medicamentosfarmaciapopular.pdf
40. Pessoto UC Helmann LS Boaretto RC Castro IEN Kayano J Ibanhes LC Junqueira V Rocha JL Barboza R Cortizo CT Martins LC Luiz OC Health care services utilizations and access inequalities in the Sao Paulo Metropolitan region Cienc Saude Coletiva 2007, 12(2):351-62 http://www.scielo.br/pdf/csc/v12n2/a11v12n2.pdf
41. Ministério da Saúde - Brasil. Programa Nacional de Controle da Tuberculose http://portal.saude.gov.br/portal/saude/ visualizar_texto.cfm?idtxt=21446
42. Ministério da Saúde - Brasil. Programa Nacional de DST e AIDS http://portal.saude.gov.br/portal/saude/visualizar_texto.cfm?idtxt= 21446
43. Ministério da Saúde - Brasil. Hiperdia - Sistema de cadastramento e acompanhamento de diabéticos e hipertensos http://hiperdia.datasus.gov.br/
44. Arkkila PE Seppala K Kosunen TU Sipponen P Makinen J Rautelin H Färkkilä M Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers Eur J Gastroenterol Hepatol 2005, 17:93-101 10.1097/00042737-200501000-00018 15647648
45. Ford AC Delaney BC Forman D Moayyedi P Eradication therapy in Helicobacter pylori positive peptic ulcer disease: Systematic review and economic analysis Am J Gastroenterol 2004, 99:1833-55 10.1111/ j.1572-0241.2004.40014.x 15330927
46. Zaterka S Eisig JN Chinzon D Rothstein W Factors related to Helicobacter pylori prevalence in adult population in Brazil Helicobacter 2007, 12:82-8 10.1111/j.1523-5378.2007.00474.x 17241306
47. Almeida Cunha RP Alves FP Rocha AM Rocha GA Camargo LM Nogueira PO Camargo EP Queiroz DM Prevalence and risk factors associated with Helicobacter pylori infection in native populations from Brazilian Western Amazon Trans R Soc Trop Med Hyg 2003, 97:382-6 10.1016/ S0035-9203(03)90063-0 15259462
48. Lira AC Santana G Santana N Silvany-Neto A Magalhães E Pereira EM Mascarenhas R Lyra MC Veiga A Ferreira K Zaterka S Lyra LG Seroprevalence and risk factors associated with Helicobacter pylori infection in blood donors in Salvador, Northeast-Brazil Braz J Infect Dis 2003, 7:339-45 14552744
49. Rodrigues MN Queiroz DMM Bezerra Filho JG Pontes LK Rodrigues LT Braga LL Prevalence of Helicobacter pylori infection in children from an urban community in north-east Brazil and risk factors for infection Eur J Gastroenterol Hepatol 2004, 16:201-5 10.1097/00042737-200402000-00013 15075995
50. Gisbert JP Gonzales L Calvet X Garcia N Lopes T Roque M Gabriel R Pajares JM Proton pump inhibitor, clarithromycin and either amoxicillin or nitroimidazole: A metanalysis of eradication of Helicobacter pylori Aliment Pharmacol Ther 2000, 14:1319-28 10.1046/j.1365-2036.2000.00844.x 11012477
51. Silva FM Zaterka S Eisig JM Chehter EZ Chinzon D Laudanna AA Factors affecting Helicobacter pylori eradication using a seven-day triple therapy with a proton pump inhibitor, tinidazole and clarithromycin in Brazilian patients with peptic ulcer Rev Hosp Clin Fac Med S Paulo 2001, 56:11-6 11378678
52. Eisig JN Andre SB Silva FM Hashimoto C Moraes-Filho JPP Laudanna AA The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy Arq Gastroenterol 2003, 40:55-60 10.1590/S0004-28032003000100012 14534667
53. Pylori Pac. Medley, Braz. Medley S.A. Indústria Farmacêutica http://www.medley.com.br/src/Area.asp?areaid= %7BCCD7A143-D80E-41B2-A191-81F0 101C3DEB%7D
54. Omepramix. Ache, Braz. Aché Laboratórios Farmacêuticos SA http://www.ache.com.br/scripts/produtos/ produto_bula.asp?idProduto=63&stProduto=Omepramix
55. Lotufo PA Benseñor IJ Lolio CA [Trends of peptic ulcer mortality in São Paulo State (Brazil) 1970-1989] Arq Gastroenterol 1994, 31:130-134 Article in Portuguese 7575172
56. Lourenço LG Hamada GS Gastric cancer in Brazil Gastric cancer 2001, 4(2):103-105 11706759 11706759 10.1007/PL00011722
57. Kitzis MD Goldstein FW Miégi M Acar JF In vitro activity of azithromycin against various gran-negative bacilli and anaerobic bacteria J Antimicrob Chemother 1990, 25(Suppl A):15-18 2154432
58. Rapp RP Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: Enhanced tissue activity and minimal drugs interactions Ann Pharmacother 1998, 32:785-93 10.1345/aph.17299 9681095
59. Bertoni G Sassatelli R Nigrisoli E Tansini P Bianchi G Della Casa G Bagni A Bedogni G Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori: A controlled trial versus omeprazole plus amoxicillin Am J Gastroenterol 1996, 91:258-63 8607489
60. Vcev A Vceva A Takac B Dmitroviæ B Stimac D Stimac T Kovac D Pezeroviæ D Blazanoviæ A Ivandiæ A Karner I Omeprazole, azithromycin and amoxicillin or amoxicillin plus clavulanic acid in eradication of Helicobacter pylori in duodenal ulcer disease Acta Med Croatica 1998, 52:209-14 9988898
61. Gribajceviæ M Vanis N Mesihoviæ R Clinical effectiveness of omeprazole, azithromycin and amoxicillin in ulcer healing and eradication of Helicobacter pylori infection Med Arh 2003, 57(1 Suppl 2):107-10 15137249
62. Krichhoff R Laufen H Schacke G Kirchhoff G Gallo E Determination of Azithromycin in gastric biopsy samples Int J Clin Pharmacol Ther 1999, 37:361-364 10442511